Precigen_January 2026.pdf

1、January 2026NASDAQ:PGEN2Forward-looking StatementThis presentation contains“forward-looking”statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995.Forward-looking statements can be identified by words such as:“anticipate,”“intend,”“plan

2、,”“goal,”“seek,”“believe,”“project,”“estimate,”“expect,”“strategy,”“future,”“likely,”“may,”“should,”“will”and similar references to future periods.These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects.Examp

3、les of forward-looking statements include,among others,information relating to the Companys business and business plans,the success of efforts to commercialize PAPZIMEOS (zopapogene imadenovec-drba)for the treatment of recurrent respiratory papillomatosis(RRP)in adults,the Companys ability to succes

4、sfully obtain foreign regulatory approvals for PAPZIMEOS,expectations about the safety and efficacy of PAPZIMEOS and the Companys other product candidates,the timing of clinical trials and their results,the Companys ability to commence clinical studies or complete ongoing clinical studies,and the ab

5、ility of PAPZIMEOS to treat RRP.The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change.All forward-looking statements are expressly qualified in their entirety by this cautionary statement.For further information on potential risks an

6、d uncertainties,and other important factors,any of which could cause the Companys actual results to differ from those contained in the forward-looking statements,see the section entitled“Risk Factors”in the Companys most recent Annual Report on Form 10-K and subsequent reports filed with the Securit